United Guardian (UG) Cash from Financing Activities (2010 - 2026)
United Guardian's (UG) quarterly Cash from Financing Activities came in at -$1.1 million in Q1 2026, up 28.48% year-over-year from -$894965.2 in Q1 2025, and little changed quarter-over-quarter from -$1.1 million in Q3 2025.
Analysis
United Guardian (UG) Cash from Financing Activities (2010 - 2026) Analysis & Trends
United Guardian has disclosed Cash from Financing Activities across 17 years of filings, most recently posting -$1.1 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 28.48% year-over-year to -$1.1 million; the TTM figure through Jun 2026 stood at -$2.3 million (up 28.75% YoY), while the FY2025 annual figure was -$2.8 million, changed 0.38% from the prior year.
- Cash from Financing Activities came in at -$1.1 million for Q1 2026 at United Guardian, roughly flat from -$1.1 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of -$10290.0 in Q2 2025 to a low of -$1.6 million in Q1 2025.
- Average Cash from Financing Activities over 5 years is -$1.1 million, with a median of -$1.1 million recorded in 2025.
- Year-over-year, Cash from Financing Activities jumped 52.3% in 2022 and tumbled 250.0% in 2024.
- Over 5 years, Cash from Financing Activities stood at -$1.4 million in 2022, then soared by 67.74% to -$459387.0 in 2023, then plunged by 250.0% to -$1.6 million in 2024, then grew by 28.57% to -$1.1 million in 2025, then slipped by 0.12% to -$1.1 million in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were -$1.1 million in Q1 2026, -$1.1 million in Q3 2025, and -$10290.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 642.70 Bn | 621.95 Bn | 17.26 Bn | -8.78 Bn |
| 2 | AbbVie | 440.80 Bn | 434.23 Bn | 12.70 Bn | -5.05 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 1.76 Bn |
| 4 | Novartis Ag | 266.37 Bn | 258.68 Bn | 11.24 Bn | -2.02 Bn |
| 5 | Pfizer | 158.89 Bn | 147.19 Bn | 10.94 Bn | -3.66 Bn |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | -2.10 Bn |
| 7 | Revolution Medicines | 44.38 Bn | 44.38 Bn | - | 2.42 Bn |
| 8 | Incyte | 25.28 Bn | 20.74 Bn | 1.57 Bn | 65.46 Mn |
| 9 | United Therapeutics | 21.46 Bn | 18.80 Bn | 683.80 Mn | 122.40 Mn |
| 10 | United Guardian | 32.67 Mn | 23.07 Mn | 1.55 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -1.15 Mn |
| Sep 30, 2025 | -1.15 Mn |
| Jun 30, 2025 | -10,290.00 |
| Mar 31, 2025 | -1.61 Mn |
| Sep 30, 2024 | -1.61 Mn |
| Mar 31, 2024 | -1.15 Mn |
| Sep 30, 2023 | -459,387.00 |
| Dec 31, 2022 | -1.42 Mn |
| Dec 31, 2021 | -2.99 Mn |
| Dec 31, 2020 | -1.65 Mn |
| Dec 31, 2019 | -2.52 Mn |
| Dec 31, 2018 | -2.52 Mn |
| Dec 31, 2017 | -4.58 Mn |
| Dec 31, 2016 | -1.83 Mn |
| Dec 31, 2015 | -2.17 Mn |
| Dec 31, 2014 | -1.47 Mn |
| Dec 31, 2013 | -2.30 Mn |
| Dec 31, 2012 | -4.32 Mn |
| Dec 31, 2011 | -2.02 Mn |
| Dec 31, 2010 | -1.52 Mn |